计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Voxtalisib (SAR245409, XL765) is a dual inhibitor ofmTOR/PI3K, mostly forp110γwithIC50of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
Targets
PI3Kγ (Cell-free assay); PI3Kα (Cell-free assay); PI3Kδ (Cell-free assay); PI3Kβ (Cell-free assay); DNA-PK (Cell-free assay) 15964,9 nM; 39 nM; 43 nM; 113 nM; 150 nM
In vitro
XL765 is active against class I PI3K (IC50 = 39, 113, 9 and 43 nM for p110α, β, γ and δ, respectively). XL765 also inhibits DNA-PK (IC50 = 150 nM) and mTOR (IC50 = 157 nM) but not XL-147 which shows IC50 values of > 15 μM. XL765 treatment results in decreased cell viability in 13 PDA cell lines in a dose-dependent manner. XL765, a dual-target PI3K/mTOR inhibitor, inhibits cell growth and apoptosis in many more cell lines and at lower concentrations as compared to the PI3K-selective inhibitors XL147 and PIK90. The effect can be recapitulated by using combinations of single-targeted compounds. XL765 significantly reduces phosphorylation of the mTOR targets S6, S6K, and 4EBP1, which is associated with greater apoptosis induction rather than to PI3K inhibition alone. XL765 treatment causes accumulation of autophagosomes in MIAPaCa-2 cells, and results in significant dose-dependent AVO induction and LC3-II stimulation in MIAPaCa-2 cells stably expressing a LC3-GFP construct.
In vivo
The combination of XL765 (30 mg/kg) with chloroquine (50 mg/kg) results in significant inhibition of BxPC-3 xenograft growth in mice models, while XL765 alone at the same dose has no inhibitory effect. Oral administration of XL765 results in greater than 12-fold reduction in median tumor bioluminescence compared to control and improvement in median survival in nude mice implanted intracranially with GBM 39-luc cells. XL765 in combination with temozolomide (TMZ) yields a 140-fold reduction in median bioluminescence with a trend toward improvement in median survival compared with TMZ alone.
Cell Research(from reference)
Cell lines:Pancreatic cancer cell lines (HcG25, Panc89, PA-TU8988T, Panc2.13, MiaPaCa2, Panc10.05, Panc8.13, BxPC-3, etc.)
Concentrations:Dissolved in DMSO, final concentration ~10 μM
Incubation Time:24, 48, 72 hours
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吡啶及其衍生物 |
| 亚类(Subclass) | 吡唑基吡啶 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 吡唑基吡啶 |
| 其他上位类(Alternative Parents) | 吡啶并[2,3-d]嘧啶 吡啶酮类 氨基嘧啶及其衍生物 吡唑类 杂芳族化合物 内酰胺类 氮杂环化合物 伯胺 有机光子化合物 有机氧化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 3-吡唑基吡啶 - 氨基酸 - 氨基吡啶 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 杂芳香族化合物 - 烃衍生物 - 肟 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 初级胺 - 吡唑 - 吡啶酮 - 吡啶并[2,3-d]嘧啶 - 吡啶吡啶 - 嘧啶 |
| 描述(Description) | 该化合物属于吡唑啉吡啶类有机化合物。这类化合物具有吡唑啉吡啶骨架,即通过键连接(而非缩合)的吡唑与吡啶结构单元。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | PI3Kδ, IC50: 43 nM |
|---|---|
| ALogP | 0.838 |
| HBD Count | 2 |
| Rotatable Bond | 2 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | V426988 |